AI-Driven Transformation: Multiply Labs Scales Deployment of Robotic Systems for Cell Therapy Manufacturing

Startup Multiply Labs is replicating the semiconductor industry’s success story in cell therapy laboratories by introducing robots to perform tedious tasks that demand stringent precision and hygiene, doing so better, faster, and more cost-effectively.

Multiply Labs provides an end-to-end robotic system for the large-scale production of genetically modified cell therapies. Its system is leveragingNVIDIA OmniverseBuild a digital twin of the laboratory environment, and leverageNVIDIA Isaac SimRobot simulation framework, training robots to master the customized skills required to develop these therapies. In addition, the company also based onNVIDIA Isaac GR00THumanoid Robot Foundation Model: Developing Humanoid Robots for Laboratory Operations to Further Enhance Cleanliness in Production Environments.

• Enhancing Precision in Laboratory Operations Through Cell Therapy Manufacturing Skill Simulation:Biotechnology companies are increasingly turning to automation and simulation technologies to reduce risks, scale up production, and systematically preserve expert knowledge. A key advancement in this area is imitation learning. By analyzing video recordings of expert operations within NVIDIA Isaac Sim, robots are trained to replicate tasks performed by humans. This approach captures the tacit, often undocumented practical skills of top scientists and translates them into executable control strategies for robots.

  
  

  Multiply Labs leverages NVIDIA Omniverse’s digital twin technology to simulate robotic arm operational workflows. This enables the company to run tens of thousands of virtual iterations prior to actual deployment, identifying and resolving nearly all mechanical issues in advance. The result is faster, safer, and more precise laboratory operations.

• Large-Scale Deployment of Robotic Systems to Enhance the Accessibility of Cell Therapy:Although cell and gene therapies hold immense potential, their complex manufacturing processes and high costs make it difficult to benefit patients on a large scale. With the aid of advanced robotics, the cost of cell therapies is expected to drop by more than 70%, while production capacity will see a significant increase, boosting therapeutic output per square foot of facility space by 100-fold.

• Leveraging Humanoid Robots to Optimize Pollution Control Processes:In the high-risk field of cell therapy manufacturing, contamination is a critical concern that cannot be overlooked. A single inadvertent sneeze, a slip of the hand, or an accidental drop of a syringe can instantly compromise the entire sterile production process. This is precisely where humanoid robots come into play. Multiply Labs is developing humanoid robots based on the NVIDIA Isaac GR00T foundation model. Leveraging Isaac GR00T, training humanoid robots to handle materials has become a scalable and reusable process. The model can transform inconsistent demonstrations from human operations into clear and reliable control policies, enabling robots to learn quickly and accelerate deployment.

The above is the abstract. Click “Read the Full Article” or scan the QR code below to read the complete content: